|
|
Post by hopingandwilling on Mar 9, 2022 11:22:24 GMT -5
Progress was made, however, appears there is still much work to do on this being a successful option for heart patients.
|
|
|
|
Post by Clement on Mar 9, 2022 11:43:41 GMT -5
Mike B, at the Cowen Healthcare Conference yesterday, said that a modified pig kidney for transplant has one genetic modification. A heart is more difficult, requiring a dozen modifications.
(Previous news about this patient indicates he was a brave soul. Salute!)
|
|
|
|
Post by uvula on Mar 9, 2022 12:10:16 GMT -5
He was ineligible for an artificial heart pump which probably means he had other medical problems in addition to a bad heart. And the article did not say the pig heart failed so he could have died from something else. We will learn at from this transplant.
|
|
|
|
Post by novafett on Mar 9, 2022 12:46:47 GMT -5
So crazy . . i'm reading a YA Fiction series by Neil Schusterman right now called Unwind. It's basically about kids who are no longer well behaved and the parents sign and order that in essence releases them to the government to "Unwind" them aka donate their body parts to people in need. 100% of their body goes to many different recipients. Seems like crazy science fiction but plausible in a lot of ways. I'm on book 4.. good popcorn read, probably be a movie soon
|
|
|
|
Post by Clement on Mar 11, 2022 15:55:00 GMT -5
Lqda dramatically drops coincidentally with strong rally by uthr. What's up?
At 3:00 pm something happened?
|
|
|
|
Post by liane on Mar 11, 2022 16:28:31 GMT -5
What I'm hearing is - Summary Judgement DENIED. Sorry, I don't have a source.
|
|
|
|
Post by Clement on Mar 11, 2022 18:03:07 GMT -5
|
|
|
|
Post by Clement on Mar 14, 2022 6:50:45 GMT -5
Liquidia 8K "On March 11, 2022, Magistrate Judge Jennifer L. Hall issued a recommendation to deny the Company’s motion on grounds that United Therapeutics did not have timely notice of the Company’s collateral estoppel argument and on grounds that the prior decision that served as the basis for collateral estoppel was decided based on a different standard of proof than the standard of proof that will apply in the Hatch-Waxman Litigation. In issuing her recommendation, Judge Hall expressly noted that she was not commenting on the validity of the asserted claims in the ‘066 or ‘901 patents or the likelihood that the Court may find the claims of the ‘066 and ‘901 patents invalid for the same reasons that the U.S. Patent Trial and Appeal Board found U.S. Patent No. 8,497,393 invalid. The parties have the opportunity to object to Judge Hall’s recommendation, after which Judge Richard G. Andrews, who is presiding over the Hatch-Waxman Litigation, will issue a decision on whether he adopts Judge Hall’s recommendation." www.liquidia.com/node/9606/html |
|
|
|
Post by sayhey24 on Mar 14, 2022 6:57:20 GMT -5
What are the ‘066 and ‘901 patents?
|
|
|
|
Post by boca1girl on Mar 15, 2022 9:08:06 GMT -5
wsw.com/webcast/oppenheimer20/register.aspx?conf=oppenheimer20&page=uthr&url=https://wsw.com/webcast/oppenheimer20/uthr/2816730
I just listened to the call and the last question asked was mine…”Any comments on the Liquida lawsuit?” The answer, with a smile was, we can’t comment on ongoing litigation.
More than 50% of the call was about T-DPI. They expect to immediately market the product in May upon approval. They also said expanded indication clinical trials are on the nebulized version and will be discussing bridging to the DPI version with the FDA.
More investment in building additional mfg capability at Danbury and at UTHR’s facility in NC is underway. Looks like we will both be producing product. It will be interesting to find out which mfg facility would be lower cost for UTHR.
Mentioned that about 70% of PAH patients will make the switch to DPI version but did not make a prediction about other indications.
They talked about the very good relationship with MNKD!
|
|
|
|
Post by sla55 on Apr 1, 2022 14:01:34 GMT -5
FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter)FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Item 1.01 Entry into a Material Definitive Agreement. On March 31, 2022, United Therapeutics Corporation (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with certain of its subsidiaries party thereto, as guarantors (the “Guarantors”), the lenders referred to therein, and Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent and as a swingline lender. The Credit Agreement provides for (i) an unsecured, revolving credit facility of up to $1.2 billion; and (ii) a second unsecured, revolving credit facility of up to $800 million (which facilities may, subject to obtaining commitments from existing or new lenders for such increase and subject to other condition, be increased by up to $500 million in the aggregate). The facilities mature five years after the closing date of the Credit Agreement, subject to an ability of the lenders thereunder, or certain of the lenders thereunder, to elect to extend the maturity date of their commitments by one year following a request for such extension by the Company in accordance with the terms of the Credit Agreement, up to a maximum of two such extensions. As of March 31, 2022, Lung Biotechnology PBC is the only subsidiary of the Company required to be a Guarantor and guarantee the Company’s obligations under the Credit Agreement. From time to time, one or more additional subsidiaries of the Company may be required to guarantee the Company’s obligations under the Credit Agreement. At the Company’s option, the loan will bear interest at either an adjusted Term SOFR rate or a fluctuating base rate, in each case, plus an applicable margin that is determined on a quarterly basis based on the Company’s consolidated total leverage ratio (as calculated in accordance with the Credit Agreement). The proceeds of borrowings under the Credit Agreement are available to refinance certain existing indebtedness of the Company and its subsidiaries and/or for working capital and other general corporate purposes. Upon closing of the Credit Agreement on March 31, 2022, the Company borrowed $800.0 million under the Credit Agreement, and used the funds to repay outstanding indebtedness under the 2018 Credit Agreement discussed under Item 1.02 below. The Credit Agreement also contains customary affirmative and negative covenants that, among other things, limit the ability of the Company and its subsidiaries to: (a) incur indebtedness; (b) grant liens; (c) enter into a merger, consolidation, or amalgamation; (d) liquidate, wind up, or dissolve; or (e) sell all or substantially all of the property, business, or assets of the Company and its subsidiaries taken as a whole. In addition, as of the last day of each fiscal quarter, the Company must not permit (i) a consolidated ratio of total indebtedness to EBITDA to be greater than 3.00 to 1.00 (which ratio may, upon consummation of certain qualifying acquisitions, be increased to 3.50 to 1.00 for four fiscal quarters following such acquisition); and (ii) its consolidated interest coverage ratio to be less than 3.00 to 1.00, in each case calculated in accordance with the Credit Agreement. The Credit Agreement contains customary events of default, including a change of control. Upon the occurrence and continuation of an event of default, all amounts due under the Credit Agreement and the other loan documents become (in the case of a bankruptcy event), or may become (in the case of all other events of default and at the option of the lenders), immediately due and payable. The foregoing summary is qualified by reference to the copy of the Credit Agreement attached hereto as Exhibit 10.1. Item 1.02 Termination of a Material Definitive Agreement. On March 31, 2022, the Company paid off and terminated all of its obligations under its Credit Agreement (the “2018 Credit Agreement”), dated as of June 27, 2018, with Wells Fargo, as administrative agent and as a swingline lender, the lenders referred to therein, and the guarantors party thereto. There were no penalties associated with the early termination of the 2018 Credit Agreement. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the Credit Agreement is incorporated herein by reference.
|
|
|
|
Post by lennymnkd on Apr 1, 2022 14:09:21 GMT -5
Big bucks ! They mean business….
|
|
|
|
Post by uvula on Apr 1, 2022 14:42:46 GMT -5
Now they can buy mnkd.
|
|
|
|
Post by mymann on Apr 1, 2022 15:59:21 GMT -5
|
|
|
|
Post by boca1girl on Apr 1, 2022 16:30:22 GMT -5
Not enough to buy out MNKD in my opinion, unless the orphan lung business is separated from the endocrine business. But no, still not enough.😎 |
|
